 |
|
|
|
 |
|
|
| Article 1 to 2 out of 2 concerning Tanox Inc
|
-
Dyax Grants Use of its Antibody Phage Display Libraries to Tanox for Therapeutic Antibody Development
(11/30/2004)
Dyax Corp. has granted a non-exclusive license to its proprietary antibody phage display libraries to Tanox, Inc. Tanox, which specializes in the development of biotherapeutics for asthma, allergy, oncology, inflammation and infectious disease, ...
-
Biotechnology Breakthrough for Asthma
(06/24/2003)
FDA approves Xolair, the first humanized antibody to target IgE, responsible for asthma with an allergic component
Genentech, Inc.Novartis Pharmaceuticals Corporation and Tanox, Inc. announced that the novel IgE-blocker XolairŽ (Omalizumab) for subcutaneous use has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-sever...
|
|
|
|
|
Top
